[Serious adverse effects with immunotherapies for the treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma: Real-world evidence study].

Date publication

octobre 2024

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Pr NERICH Virginie

Tous les auteurs :
Cuenot L, Valnet-Rabier MB, Bendjama A, Aubin F, Fischer S, Viot J, Nerich V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39389873

Résumé

Immune checkpoint inhibitors (ICIs) are a key component of standard anticancer systemic therapy. While their immune-related adverse effects (irAEs) have been widely described, there are few data on grade≥3 irAEs. The primary aim of our descriptive study was to evaluate their incidence and characteristics.

Mots clés

Cancer bronchique non à petites cellules, Carcinome à cellules rénales, Effets indésirables immunitaires, Immune checkpoint inhibitors, Immune-related adverse events, Immunothérapie inhibitrice des points de contrôle immunitaire, Melanoma, Non-small cell lung cancer, Renal cell carcinoma

Référence

Bull Cancer. 2024 10 9;: